Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan

Efthimou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis. 2006;65:564–72. Ohta A, Yamaguchi M, Tsunematsu T, Kasukawa R, Mizushima H, Kashiwagi H, et al. Adult Still’s disease: a multicenter survey of Japanese patients. J Rheumatol. 1990;17:1058–63. Choi J-H, Suh C-H, Lee Y-M, Suh Y-J, Lee S-K, Kim S-S, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30:2422–7. Chen D-Y, Lan J-L, Lin F-J, Hsieh T-Y. Proinflamatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31:2189–98. Hoshino T, Ohta A, Yang D, Kawamoto M, Kikuchi M, Inoue Y, et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still’s disease. J Rheumatol. 1998;25:396–8. Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still’s disease. Semin Arthritis Rheum. 2006;36:144–52. Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum. 2010;62:2530–5. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52:1794–803. Fautrel B, Sibilia J, Mariette X, Combe B; Club Rheumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–6. Cavagna L, Caporali R, Epis O, Bobbio-Pallavini F, Montecucco C. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol. 2001;19:329–32. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis. 2001;60[Suppl 3]:iii55–7. Kokkinos A, Iliopoulos A, Greka P, et al. Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol. 2004;23:45–9. Tamesis ER, Reginato AM, Hubscher O, Reginato AJ. Etanercept in recalcitrant adult onset Still’s disease. Arthritis Rheum. 2000;43:S229. Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Garvallese EM, et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum. 2002;46:1171–6. Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease. Ann Rheum Dis. 2010;69:466–7. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:961–3. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthritis Rheum. 2002;46:3388–9. De Bandt M, Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still’s disease. Ann Rheum Dis. 2009;68:153–4. Kishida D, Okuda Y, Onishi M, Takebayashi M, Matoba K, Joutama K, et al. Successful tocilizumab treatment in patient with adult-onset Still’s disease complicated by chronic active hepatitis B and amyloid A amyloidisis. Mod Rheumatol. 2011;21:215–8. Matsumoto K, Nagashima T, Takatori S, Kawahara Y, Yagi M, Iwamoto M, et al. Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab. Cin Rheumatol. 2009;28:485–7. Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol. 2009;19:69–72. Sumida K, Ubara Y, Hoshino J, Suwabe T, Hiramatsu R, Hasegawa E, et al. Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol. 2010;29:1191–4. Naniwa T, Ito R, Watanabe M, Hayami Y, Maeda S, Sasaki K, et al. Successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still’s disease. Clin Rheumatol. 2010. [Epub ahead of print]. Sabnis GR, Gokhale YA, Kulkarni UP. Tocilizumab in refractory adult-onset Still’s disease with aseptic meningitis-efficacy of interleoukin-6 blockade and review of the literature. Semin Arthritis Rheum. 2011;40:365–8. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Güler-Yüksel M, Zwinderman AH, Kerstens PJ, et al. Drug-free remission, and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:914–21. Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic disease. J Rheumatol. 2010;37:967–73. Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, et al. Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and review of the literature. Ann Rheum Dis. 2006;65:1596–601. Mitamura M, Tada Y, Koarada S, Inoue H, Suematsu R, Ohta A, et al. Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease. Mod Rheumatol. 2009;19:57–63. Kaneko K, Kaburaki M, Muraoka S, Tanaka N, Yamamoto T, Kusunoki Y, et al. Exacerbation of adult-onset Still’s disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis. 2010;13:e67–9. Gianella S, Schaer DJ, Schwarz U, Kurrer M, Heppner FL, Fehr J, Seebach JD. Retinal microangiopathy and rapidly fatal cerebral edema in patient with adult-onset Still’s disease and concurrent macrophage activation syndrome. Am J Hematol. 2008;83:424–7. Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still’s disease after initiation of etanercept therapy. J Clin Rheumatol. 2001;7:252–6. Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92–6. Puéchal X, DeBandt M, Berthelot JM, Mreban M, Dubost JJ, Fain O, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res. 2011;63:155–9.